Trial Profile
PLENO – Open-label, Randomized, 2-arm, Active Comparator Study to Evaluate Safety and Tolerability in Portuguese Patients with Relapsing Remitting Multiple Sclerosis (MS) Transitioning from Current Subcutaneous Interferon Therapy to Peginterferon Beta 1a (PLEGRIDY™)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Jan 2024
Price :
$35
*
At a glance
- Drugs Peginterferon beta-1a (Primary) ; Interferon beta-1a; Interferon beta-1b
- Indications Multiple sclerosis
- Focus Adverse reactions
- Acronyms PLENO
- Sponsors Biogen
- 23 Nov 2020 Status changed from active, no longer recruiting to completed.
- 02 Dec 2019 Planned End Date changed from 30 Mar 2020 to 30 Sep 2020.
- 02 Dec 2019 Planned primary completion date changed from 30 Mar 2020 to 30 Sep 2020.